Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
yinlitinib
- Development stage
- Unknown
- Lead developer
- Dongguan Dongyangguang Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Yinlitinib (also known as yinlitinib maleate) is an orally bioavailable, small molecule multi-kinase inhibitor developed by Guangdong Dongyangguang Pharmaceutical (HEC Pharm). It is designed to target several receptor tyrosine kinases (RTKs) that play critical roles in tumor angiogenesis, lymphangiogenesis, and cell proliferation. Specifically, yinlitinib inhibits the vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, and VEGFR-3), platelet-derived growth factor receptors (PDGFR), and the mast/stem cell growth factor receptor (c-Kit). By blocking these signaling pathways, the drug aims to suppress the formation of new blood vessels that support tumor growth and directly interfere with oncogenic signaling in tumor cells. Yinlitinib has been investigated in Phase 1 clinical trials in China for the treatment of advanced solid tumors.
- Other names
- yinlitinib maleate马来酸因利替尼
02
Targets
KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)PDGFR (PDGFR family)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR3 (Vascular endothelial growth factor receptor 3)
Beyond the preview
Go deeper on yinlitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on yinlitinib.